- Conditions
- Breast Cancer
- Interventions
- Not listed
- Lead sponsor
- Breathe BioMedical Inc
- Industry
- Eligibility
- 40 Years to 74 Years · Female only
- Enrollment
- 5,175 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2028
- U.S. locations
- 4
- States / cities
- Washington D.C., District of Columbia • Jacksonville, Florida • Durham, North Carolina + 1 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
The live registry is temporarily unavailable. These stored records may be incomplete or out of date. Check the official record for current status and contact information.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 529–552
of 2,462
matching trials from the local directory fallback.
- Conditions
- Atrial Fibrillation, Stroke, Ischemic, Systemic Embolism
- Interventions
- WATCHMAN device
- Device
- Lead sponsor
- Hamilton Health Sciences Corporation
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 4,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 53
- States / cities
- Birmingham, Alabama • Jonesboro, Arkansas • Fountain Valley, California + 48 more
- Conditions
- Heterozygous or Homozygous Familial Hypercholesterolemia
- Interventions
- Inclisiran
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 2 Years to 100 Years
- Enrollment
- 195 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2032
- U.S. locations
- 5
- States / cities
- Boca Raton, Florida • New York, New York • Cincinnati, Ohio + 2 more
- Conditions
- Autoimmune Disorders
- Interventions
- Placebo for Ublituximab, Ublituximab
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 8
- States / cities
- Birmingham, Alabama • Atlanta, Georgia • Chicago, Illinois + 5 more
- Conditions
- Cervical Adenocarcinoma, Colorectal Adenocarcinoma, Head and Neck Cancer, Hormone Receptor Positive Breast Adenocarcinoma, Non Small Cell Lung Cancer, Triple Negative Breast Cancer (TNBC), Urothelial Carcinoma Bladder
- Interventions
- [225Ac]Ac-AKY-1189 (therapeutic), [64Cu]Cu-AKY-1189 (imaging)
- Drug
- Lead sponsor
- Aktis Oncology, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2032
- U.S. locations
- 14
- States / cities
- Duarte, California • Irvine, California • Miami, Florida + 10 more
- Conditions
- Status Epilepticus
- Interventions
- Levetiracetam (LEV) (60 mg/Kg), Levetiracetam (LEV) (60 mg/Kg) + 1 mg/kg Ketamine (KET), Levetiracetam (LEV) (60 mg/Kg) + 3 mg/kg Ketamine (KET)
- Drug
- Lead sponsor
- University of Virginia
- Other
- Eligibility
- 1 Year and older
- Enrollment
- 770 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 63
- States / cities
- Birmingham, Alabama • Tucson, Arizona • La Jolla, California + 38 more
- Conditions
- Hemorrhagic Shock, Trauma Injury
- Interventions
- Component Therapy (CT), Low Titer Group O Whole Blood (LTOWB), Placebo, Tranexamic Acid (TXA)
- Biological · Drug
- Lead sponsor
- Philip Spinella
- Other
- Eligibility
- Up to 17 Years
- Enrollment
- 1,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 23
- States / cities
- Tucson, Arizona • Little Rock, Arkansas • Sacramento, California + 18 more
- Conditions
- Emphysema or COPD, Emphysema, Pulmonary
- Interventions
- AeriSeal System
- Device
- Lead sponsor
- Pulmonx Corporation
- Industry
- Eligibility
- 40 Years to 80 Years
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 20
- States / cities
- Phoenix, Arizona • Loveland, Colorado • Hartford, Connecticut + 13 more
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Allogeneic Hematopoietic Stem Cell Transplantation, Asparaginase Erwinia chrysanthemi, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Cytarabine, Daunorubicin Hydrochloride, Dexrazoxane Hydrochloride, Etoposide, Fludeoxyglucose F-18, Gemtuzumab Ozogamicin, Gilteritinib Fumarate, Liposome-encapsulated Daunorubicin-Cytarabine, Magnetic Resonance Imaging, Methotrexate, Mitoxantrone Hydrochloride, Positron Emission Tomography, Questionnaire Administration, Therapeutic Hydrocortisone
- Procedure · Drug · Other
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 6 Months to 21 Years
- Enrollment
- 1,400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2029
- U.S. locations
- 186
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Mesa, Arizona + 143 more
- Conditions
- Chronic Weight Management, Obesity, Overweight, Type 2 Diabetes Mellitus
- Interventions
- ASC30 tablets A1, Placebo
- Drug
- Lead sponsor
- Ascletis Pharma (China) Co., Limited
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,560 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 84
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Peoria, Arizona + 80 more
- Conditions
- Chemotherapy Induced Peripheral Neuropathy (CIPN), Diabetic Peripheral Neuropathic Pain (DPN), Idiopathic Peripheral Neuropathy, Painful Peripheral Neuropathy
- Interventions
- Duloxetine, Placebo, Pregabalin
- Drug · Other
- Lead sponsor
- University of Rochester
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 190 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 7
- States / cities
- Boston, Massachusetts • New York, New York • Rochester, New York + 4 more
- Conditions
- Alpha-fetoprotein (AFP)-Producing Gastric Cancer, Extragonadal Yolk Sac Tumors, Glypican-3 (GPC3)-Positive Squamous Non-small Cell Lung Cancer, Local Advanced Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma
- Interventions
- BGB-B2033, Bevacizumab, Tislelizumab
- Drug
- Lead sponsor
- BeOne Medicines
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 630 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 8
- States / cities
- Birmingham, Alabama • Goodyear, Arizona • Duarte, California + 5 more
- Conditions
- Liver Transplant
- Interventions
- CMV-MVA Triplex, Placebo for CMV-MVA Triplex
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 416 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 18
- States / cities
- Birmingham, Alabama • La Jolla, California • Redwood City, California + 15 more
- Conditions
- Cardiovascular Diseases, Cerebrovascular Disorders, Psychological Stress
- Interventions
- Paced Auditory Serial Addition Task
- Behavioral
- Lead sponsor
- University of Pittsburgh
- Other
- Eligibility
- 40 Years to 59 Years
- Enrollment
- 450 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2029
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Acoustic Stimulation
- Interventions
- Acoustic Stimulation (STIM), Daily acoustic stimulation (STIM2), No Acoustic Stimulation (SHAM), No daily acoustic stimulation (SHAM2)
- Device
- Lead sponsor
- Michelle Stepan
- Other
- Eligibility
- 18 Years to 25 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Hematologic, Immune, or Bone Marrow Disorders, Hemoglobinopathies, Metabolic Disorders, Non-malignant Disorders
- Interventions
- GVHD Regimen A: UCB Recipients, GVHD Regimen B: BM Recipients, Treatment Plan 1: Stratum 1, Treatment Plan 2: Strata 2, 3, or 4
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- Up to 20 Years
- Enrollment
- 220 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2031
- U.S. locations
- 25
- States / cities
- Phoenix, Arizona • Orange, California • San Diego, California + 20 more
- Conditions
- Myelomeningocele, Spina Bifida
- Interventions
- Transcutaneous stimulator
- Device
- Lead sponsor
- Bailey Petersen
- Other
- Eligibility
- 4 Years to 17 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Metastatic Castration-resistant Prostate Cancer (mCRPC)
- Interventions
- Xaluritamig
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 12
- States / cities
- Denver, Colorado • Durham, North Carolina • Cincinnati, Ohio + 7 more
- Conditions
- Disabled Veterans, Families of Veterans, Family Caregivers, Spinal Cord Injuries (Complete and Incomplete), Spinal Cord Injuries (SCI), Spinal Cord Injury
- Interventions
- iMHERE 2.0. A mobile health App designed to support veterans with SCI manage their self care, and their caregivers
- Other
- Lead sponsor
- University of Pittsburgh
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2029
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Clinical Stage 0 Cutaneous Melanoma AJCC v8, Clinical Stage I Cutaneous Melanoma AJCC v8, Clinical Stage II Cutaneous Melanoma AJCC v8, Clinical Stage III Cutaneous Melanoma AJCC v8, Cutaneous Dysplastic Nevus
- Interventions
- Biopsy Procedure, Biospecimen Collection, Placebo Administration, Sulforaphane
- Procedure · Drug
- Lead sponsor
- ECOG-ACRIN Cancer Research Group
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2033
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- CML, CML, Chronic Phase, Chronic Myeloid Leukemia
- Interventions
- Bosutinib, olverembatinib
- Drug
- Lead sponsor
- Ascentage Pharma Group Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 333 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 50
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Goodyear, Arizona + 44 more
- Conditions
- Myositis
- Interventions
- PF-06823859, Placebo
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 318 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2030
- U.S. locations
- 45
- States / cities
- Glendale, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 22 more
- Conditions
- Acute Ischemic Stroke, Cerebral Stroke
- Interventions
- Drug: Normal Saline, Sovateltide
- Drug
- Lead sponsor
- Pharmazz, Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 514 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 14
- States / cities
- Tucson, Arizona • Carmichael, California • Oxnard, California + 10 more
- Conditions
- Acral Lentiginous Melanoma, Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Cutaneous Melanoma, Metastatic Malignant Neoplasm in the Brain, Metastatic Melanoma, Metastatic Mucosal Melanoma, Pathologic Stage IV Cutaneous Melanoma AJCC v8
- Interventions
- Binimetinib, Encorafenib, Ipilimumab, Nivolumab
- Drug · Biological
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 112 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 331
- States / cities
- Birmingham, Alabama • Fairhope, Alabama • Mobile, Alabama + 234 more